Edwards Lifesciences Corp (EW) concluded trading on Wednesday at a closing price of $75.47, with 4.87 million shares of worth about $367.87 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 5.51% during that period and on June 11, 2025 the price saw a loss of about -0.44%. Currently the company’s common shares owned by public are about 586.20M shares, out of which, 574.70M shares are available for trading.
Stock saw a price change of -3.06% in past 5 days and over the past one month there was a price change of 0.90%. Year-to-date (YTD), EW shares are showing a performance of 1.95% which decreased to -14.37% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $58.93 but also hit the highest price of $95.25 during that period. The average intraday trading volume for Edwards Lifesciences Corp shares is 4.69 million. The stock is currently trading -1.91% below its 20-day simple moving average (SMA20), while that difference is up 1.57% for SMA50 and it goes to 5.91% higher than SMA200.
Edwards Lifesciences Corp (NYSE: EW) currently have 586.20M outstanding shares and institutions hold larger chunk of about 87.85% of that.
The stock has a current market capitalization of $44.27B and its 3Y-monthly beta is at 1.12. PE ratio of stock for trailing 12 months is 50.42, while it has posted earnings per share of $1.50 in the same period. Its PEG reads 5.89 and has Quick Ratio of 3.66 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EW, volatility over the week remained 0.53% while standing at 1.07% over the month.
Stock’s fiscal year EPS is expected to rise by 1.65% while it is estimated to increase by 11.53% in next year. EPS is likely to grow at an annualized rate of 8.56% for next 5-years, compared to annual growth of -2.36% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on April 24, 2025 offering an Overweight rating for the stock and assigned a target price of $80 to it. Coverage by Stifel stated Edwards Lifesciences Corp (EW) stock as a Buy in their note to investors on January 30, 2025, suggesting a price target of $90 for the stock. Stock get an Equal-weight rating from Morgan Stanley on October 11, 2024.
